NCT06995586 - Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery. | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2028

Conditions

Cardio-pulmonary BypassCardiovascular DiseasesOmega-3 Polyunsaturated Fatty AcidsOmega-3 SupplementationVitamin CSupplementsPostoperative DepressionAntioxidantsLactulosePostoperativeOptimal Medical TherapyCABGCoronary Artery Bypass GraftingPrebiotics

Interventions

DIETARY_SUPPLEMENT

Vitamin C, Omega 3 PUFA (EPO/DHA), Lignin, Lactulose

This is a randomized and controlled trial with an intervention group that will be administered orally daily in addition to the Optimal Medical Therapy (OMT), namely 1000 mg Vitamin C, 840 mg EPO/DHA, 2130 mg Lignin \& 720 mg Lactulose and a control group that will receive only the OMT.

Trial Locations (1)

2031

Nicosia General Hospital, Stróvolos